Max Noble
Menu
CEO Storm Watch · the report4 August 2026

Max Noble

Novo Nordisk

Maziar Mike Doustdar promised sales down 5–13% in 2026. Delivered: promise raised twice, to 0 to −6%.

🇩🇰 Denmark · MedicinesNovo Nordisk0.0IntegrityMaziar Mike DoustdarMaziar Mike DoustdarPresident & CEO, 2025–, Novo NordiskPromisedsales in 2026−5 to −13%3 February 2026

Last checked · How I check · Follow this CEO

He promised

Sales would drop 5 to 13% in 2026, leaving out a one-off refund.

Maziar Mike Doustdar, President & CEO, 2025–, on 3 February 2026.

He got

Raised twice: now a drop of 0 to 6%. Sales grew 2% in the first half.

Stamp: On track.

Why, says the company

It now expects to sell more of its diabetes and weight-loss medicines, in the US and abroad.

How bad

Nothing yet: the promise was raised. The 2026 annual report settles it. The CEO’s Integrity Score went from 0.0 to 0.0.

In the company’s own words

The company raised its outlook mainly on higher expectations for sales of its GLP-1 medicines (for diabetes and weight loss), with growth and new launches outside the US.

The sources

Last checked 1 November 2026: the sources were opened again and the promise and the stamp still stand. How I check.

How the Max Noble Odds moved

Odds: 55% before the first call → verdict expected on 3 February 2027

The chance of Yes to “Will Novo Nordisk's sales drop less than 3% in 2026?” The first number is my starting estimate; every call moves it. One point a day is kept from 8 November 2026 to the verdict.

Will Novo Nordisk's sales drop less than 3% in 2026? Make your call in The Power Game →

Follow this CEO

Get an email the morning Maziar Mike Doustdar’s card turns.

One email when the stamp changes or a new promise is checked. Nothing else.

Your choices
Your editions
How often
Breaking Briefs

Next: read today’s Morning Brief →